title: Vaccination of diffuse large B- cell lymphoma patients with antigen-primed dendritic cells.
abstract: Dendritic cells (DCs) are professional antigen presenting cells that have a potential role in the initiating of immune responses. The cell vaccination is a new strategy in treatment of infectious diseases and cancers. In this study, we have generated monocyte-derived dendritic cells of lymphoma patient's peripheral blood mononuclear cells then; these cells were used as vaccine in lymphoma patients. We generated dendritic cell vaccine from lymphoma patient's blood monocytes with human interleukin-4, granulocyte monocyte colony stimulating factor and then, antigen-primed Dcs were administrated subcutaneously close to the inguinal lymph nodes after maturation of dendritic cells. After 7 days, we analyzed immune response in lymphoma patients with determining of LDH, Beta 2 Microglobulin, CD4+T cell percent, CD8+ Tcell percent and Tumor size before and after vaccination. Furthermore, phenotypic and functional analysis of dendritic cells was performed using anti CD83-FITC monoclonal antibodies. Before vaccination, the mean ± SD of LDH was 530.62±140.65 but after vaccination it was 459±109.45 that significantly different between experimental groups (P=0.002). In addition, the CD8+ T cells percentage significantly different between two groups (P=0.002). We concluded that the use of dendritic cell probably is one of the suitable noninvasive treatments for lymphoma patients that they have not response to chemical drugs.
authors.affiliation: Department of Immunology, Immonogenetic Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran. abedianks@razi.tums.ac.ir
authors.forename: Saeid
authors.initials: S
authors.lastname: Abediankenari
authors.forename: Ghasem
authors.initials: G
authors.lastname: Janbabaei Mollae
authors.forename: Maryam
authors.initials: M
authors.lastname: Ghasemi
authors.forename: Yousef
authors.initials: Y
authors.lastname: Yousefzadeh
authors.forename: Masoud
authors.initials: M
authors.lastname: Bahrami
authors.forename: Kamran
authors.initials: K
authors.lastname: Alimoghaddam
mesh_terms: D000293:Adolescent; D000328:Adult; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000627:therapeutic use*; D003713:Dendritic Cells / Q000276:immunology*; D005260:Female; D005434:Flow Cytometry; D005500:Follow-Up Studies; D006801:Humans; D007111:Immunity, Cellular; D007279:Injections, Subcutaneous; D016403:Lymphoma, Large B-Cell, Diffuse / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D013601:T-Lymphocytes / Q000276:immunology; D016896:Treatment Outcome; D014407:Tumor Cells, Cultured; D014611:Vaccination / Q000379:methods*; D055815:Young Adult
chemical_list: D019496:Cancer Vaccines